Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q92643
UPID:
GPI8_HUMAN
Alternative names:
GPI8 homolog; Phosphatidylinositol-glycan biosynthesis class K protein
Alternative UPACC:
Q92643; B2R7K3; B4E2M3; O14822; Q5TG77
Background:
The GPI-anchor transamidase, also known as GPI8 homolog and Phosphatidylinositol-glycan biosynthesis class K protein, plays a crucial role in the post-translational modification of proteins. It is essential for the attachment of GPI (glycosylphosphatidylinositol) anchors to proteins in the endoplasmic reticulum. This process is vital for the proper localization and function of GPI-anchored proteins.
Therapeutic significance:
The GPI-anchor transamidase is linked to a neurodevelopmental disorder characterized by hypotonia, cerebellar atrophy, and potential seizures. Understanding the role of GPI-anchor transamidase could open doors to potential therapeutic strategies for treating this disorder and improving patient outcomes.